Baricitinib in the Treatment of New-onset Juvenile Dermatomyositis (MYOCIT)
Status:
Not yet recruiting
Trial end date:
2026-08-01
Target enrollment:
Participant gender:
Summary
The MYOCIT study aims to evaluate the efficacy and safety of baricitinib in association with
corticosteroids in new-onset patients with juvenile dermatomyositis (JDM) in a phase II trial
with the objective to obtain a better efficacy than the conventional combination methotrexate
(MTX) and corticosteroids over the 24 week study period. Thus, the investigators hypothesize
that baricitinib could be used as a first line treatment in all forms of DMJ, including the
most severe one, with a good safety profile.